EpiVax launches EpiVax Oncology for personalized cancer vaccines

EPIVAX PRESIDENT AND CEO Dr. Anne S. De Groot. EpiVax has launched a venture-backed spinoff, Epivax Oncology. / PBN FILE PHOTO
EPIVAX PRESIDENT AND CEO Dr. Anne S. De Groot. EpiVax has launched a venture-backed spinoff, Epivax Oncology. / PBN FILE PHOTO
PROVIDENCE — Immunolgy engineering biotech firm EpiVax Inc. has launched EpiVax Oncology Inc., a venture-backed spinoff focused on the development of personalized therapeutic cancer vaccines. EpiVax Oncology, an independent company, is conducting a $2 million bridge capital raise to prepare for an Investigational New Drug application as well as a $10 million to $25 million…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -